Astellas Pharma (OTCMKTS:ALPMY) Cut to Hold at Zacks Research

Zacks Research cut shares of Astellas Pharma (OTCMKTS:ALPMY) from a strong-buy rating to a hold rating in a research note released on Wednesday,Zacks.com reports.

Separately, Jefferies Financial Group upgraded Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

Astellas Pharma Stock Up 0.9%

Astellas Pharma stock opened at $13.21 on Wednesday. The firm has a market capitalization of $23.90 billion, a price-to-earnings ratio of 12.30 and a beta of 0.07. The firm’s fifty day moving average price is $13.48 and its two-hundred day moving average price is $14.63. Astellas Pharma has a 1-year low of $9.91 and a 1-year high of $17.35. The company has a current ratio of 1.17, a quick ratio of 0.90 and a debt-to-equity ratio of 0.17.

Astellas Pharma (OTCMKTS:ALPMY) last posted its earnings results on Monday, April 27th. The company reported $0.33 EPS for the quarter, topping the consensus estimate of $0.19 by $0.14. Astellas Pharma had a net margin of 13.66% and a return on equity of 23.54%. The company had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.28 billion. On average, equities research analysts predict that Astellas Pharma will post 1.25 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).